ATE490783T1 - Nicht-depletierender antikörper trx-1 gegen cd4 und dessen verwendungen - Google Patents

Nicht-depletierender antikörper trx-1 gegen cd4 und dessen verwendungen

Info

Publication number
ATE490783T1
ATE490783T1 AT02730530T AT02730530T ATE490783T1 AT E490783 T1 ATE490783 T1 AT E490783T1 AT 02730530 T AT02730530 T AT 02730530T AT 02730530 T AT02730530 T AT 02730530T AT E490783 T1 ATE490783 T1 AT E490783T1
Authority
AT
Austria
Prior art keywords
depleting antibody
trx
antibody trx
antigen
antibody
Prior art date
Application number
AT02730530T
Other languages
English (en)
Inventor
Mark Frewin
Herman Waldmann
Scott Gorman
Geoff Hale
Patricia Rao
Tadeusz Kornaga
Douglas Ringler
Stephen Cobbold
Dawn Winsor-Hines
Original Assignee
Isis Innovation
Cambridge Entpr Ltd
Tolerx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0114517A external-priority patent/GB2376466A/en
Application filed by Isis Innovation, Cambridge Entpr Ltd, Tolerx Inc filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE490783T1 publication Critical patent/ATE490783T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT02730530T 2001-06-14 2002-06-14 Nicht-depletierender antikörper trx-1 gegen cd4 und dessen verwendungen ATE490783T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0114517A GB2376466A (en) 2001-06-14 2001-06-14 TRX1 antibody
GB0122724A GB2376467A (en) 2001-06-14 2001-09-20 TRX1 Antibodies
US34519401P 2001-10-19 2001-10-19
US37347102P 2002-04-18 2002-04-18
US37347002P 2002-04-18 2002-04-18
PCT/GB2002/002796 WO2002102853A2 (en) 2001-06-14 2002-06-14 Cd4-specific antibody trx1 and uses therefor

Publications (1)

Publication Number Publication Date
ATE490783T1 true ATE490783T1 (de) 2010-12-15

Family

ID=27516025

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02730530T ATE490783T1 (de) 2001-06-14 2002-06-14 Nicht-depletierender antikörper trx-1 gegen cd4 und dessen verwendungen

Country Status (7)

Country Link
EP (3) EP1395284B1 (de)
JP (1) JP4448906B2 (de)
AT (1) ATE490783T1 (de)
AU (1) AU2002302848C8 (de)
CA (1) CA2450700A1 (de)
DE (1) DE60238533D1 (de)
WO (1) WO2002102853A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
EP1460088A1 (de) 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
US20050048587A1 (en) * 2003-07-17 2005-03-03 Tolerrx, Inc. Methods for identifying tolerance modulatory compounds and uses therefor
MXPA06000176A (es) * 2003-12-10 2006-06-27 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y sus metodos de uso.
CA2570849A1 (en) * 2004-06-22 2006-01-05 Tolerrx, Inc. Optimized dosing with anti-cd4 antibodies for tolerance induction in primates
EP1913387B1 (de) * 2005-08-02 2016-01-20 Centenary Institute of Cancer Medicine & Cell Biology Verfahren zur identifizierung regulatorischer t-zellen
EP2260057B1 (de) 2008-03-13 2016-11-23 Biotest AG Anti-CD4 Antikörper Dosierungsschema zur Behandlung von Autoimmunkrankheiten
RU2540013C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
EP2265643B1 (de) 2008-03-13 2016-10-19 Biotest AG Dosierungsschema zur behandlung von psoriasis und rheumatoider arthritis
JP5913980B2 (ja) 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド 免疫グロブリン変異体及びその用途
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP4381081A1 (de) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Verwendung von auf cd4 gerichteten viralen vektoren
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
EP4463135A2 (de) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Verfahren zur ex-vivo-dosierung und -verabreichung von lipidpartikeln oder viralen vektoren sowie entsprechende systeme und verwendungen
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
EP4716750A1 (de) 2023-05-23 2026-04-01 Sana Biotechnology, Inc. Tandem-fusogene und verwandte lipidpartikel
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8912497D0 (en) * 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
CA2221350A1 (en) * 1995-05-18 1996-11-21 Ortho Pharmaceutical Corporation Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies

Also Published As

Publication number Publication date
JP2005508296A (ja) 2005-03-31
JP4448906B2 (ja) 2010-04-14
EP2345424A1 (de) 2011-07-20
WO2002102853A2 (en) 2002-12-27
AU2002302848B2 (en) 2008-07-17
EP1985306A3 (de) 2009-04-01
DE60238533D1 (de) 2011-01-20
EP1985306A2 (de) 2008-10-29
AU2002302848C1 (en) 2008-12-11
AU2002302848C8 (en) 2010-02-04
EP1395284B1 (de) 2010-12-08
CA2450700A1 (en) 2002-12-27
EP1395284A2 (de) 2004-03-10
WO2002102853A3 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
ATE490783T1 (de) Nicht-depletierender antikörper trx-1 gegen cd4 und dessen verwendungen
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
ATE373016T1 (de) Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers
ATE389721T1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
AU9399501A (en) Therapeutic antibodies
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
EP1573002A4 (de) Antikörpervarianten mit schnelleren antigenassoziations geschwindigkeiten
IL221708A0 (en) Polyclonal goat anti-hla class ii antibody for treatment of disease involving proliferative immune response
BR0009154A (pt) Vacina
TW200509930A (en) Methods and compositions for treating rheumatoid arthritis
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
NZ595450A (en) Antibodies to M-CSF
ATE470714T1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
FR13C0068I2 (fr) Conjugues du maytansinoide dm1 avec l'anticorps trastuzumab, attache par une liaison non-clivable, et son utilisation dans le traitement des tumeurs.
PL1639011T3 (pl) Pegilowane przeciwciała jednodomenowe (dAb)
ATE267610T1 (de) Glykosylierte igg antikörper
ES2124533T3 (es) Anticuerpos monoclonales inmunoestimulantes.
MXPA02000419A (es) Bloqueo de la respuesta inmune a un antigeno extrano utilizando un antagonista que se enlaza a cd20.
WO2003026692A3 (en) Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex
EP1558284A4 (de) Kombinationstherapie mit klasse iii anticea monoklonalen antikörpern und therapeutischen wirkstoffen
FR2841905B1 (fr) Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
GB0008305D0 (en) Treatment of fungal infections
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
ATE435020T1 (de) Oligo-beta-(1,3)-glucan und monoklonale antikörper gegen krebs
ES2096588T3 (es) Anticuerpos monoclonales para inducir tolerancia.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties